机构:[1]Department of Cardiothoracic Surgery, Hebei Medical University Fourth Hospital, ShiJiaZhuang, Hebei, P. R. China河北医科大学第四医院[2]SurExam Bio-Tech Co. Ltd., Guangzhou Technology Innovation Base, Science City, Guangzhou, P. R. China
The fatality rate of esophageal carcinomas is high in developing countries, making effective treatment desirable. Traditional treatment has now entered into the platform, and treatments based on the detection of biomarkers increasingly become a trend. This review presents several biomarkers of esophageal cancer, including chemotherapy-related biomarkers and targeted drug-related biomarkers, and the correlation of these biomarkers with drug response.
第一作者机构:[1]Department of Cardiothoracic Surgery, Hebei Medical University Fourth Hospital, ShiJiaZhuang, Hebei, P. R. China
通讯作者:
通讯机构:[2]SurExam Bio-Tech Co. Ltd., Guangzhou Technology Innovation Base, Science City, Guangzhou, P. R. China[*1]SurExam Bio-Tech Co. Ltd., Guangzhou Technology Innovation Base, Science City, Guangzhou, P. R. China
推荐引用方式(GB/T 7714):
Wang Lei,Yang Hui-Yi,Zheng Yong-Qing.Personalized medicine of esophageal cancer[J].JOURNAL OF CANCER RESEARCH AND THERAPEUTICS.2012,8(3):343-347.doi:10.4103/0973-1482.103510.
APA:
Wang, Lei,Yang, Hui-Yi&Zheng, Yong-Qing.(2012).Personalized medicine of esophageal cancer.JOURNAL OF CANCER RESEARCH AND THERAPEUTICS,8,(3)
MLA:
Wang, Lei,et al."Personalized medicine of esophageal cancer".JOURNAL OF CANCER RESEARCH AND THERAPEUTICS 8..3(2012):343-347